Brain alterations in Cocaine Use Disorder: Does the route of use matter and does it relate to the treatment outcome?

Alterations Cocaine use disorder Crack-cocaine Relapse Severity Treatment Outcome Voxel-based morphometry

Journal

Psychiatry research. Neuroimaging
ISSN: 1872-7506
Titre abrégé: Psychiatry Res Neuroimaging
Pays: Netherlands
ID NLM: 101723001

Informations de publication

Date de publication:
22 May 2024
Historique:
received: 06 12 2023
revised: 15 04 2024
accepted: 12 05 2024
medline: 1 6 2024
pubmed: 1 6 2024
entrez: 31 5 2024
Statut: aheadofprint

Résumé

Cocaine Use Disorder (CUD) is an important health issue, associated with structural brain abnormalities. However, the impact of the route of administration and their predictive value for relapse remain unknown. We conducted an anatomical MRI study in 55 CUD patients (26 CUD-Crack and 29 CUD-Hydro) entering inpatient detoxification, and 38 matched healthy controls. In patients, a 3-months outpatient follow-up was carried out to specify the treatment outcome status (relapser when cocaine was consumed once or more during the past month). A Voxel-Based Morphometry approach was used. Compared with controls, CUD patients had widespread gray matter alterations, mostly in frontal and temporal cortices, but also in the cerebellum and several sub-cortical structures. We then compared CUD-Crack with CUD-Hydro patients and found that crack-cocaine use was associated with lower volume in the right inferior and middle temporal gyri, and the right fusiform gyrus. Cerebellar vermis was smaller during detoxification in subsequent relapsers compared to three-months abstainers. Patients with CUD display widespread cortical and subcortical brain shrinkage. Patients with preferential crack-cocaine use and subsequent relapsers showed specific gray matter volume deficits, suggesting that different patterns of cocaine use and different clinical outcome are associated with different brain macrostructure.

Identifiants

pubmed: 38820804
pii: S0925-4927(24)00053-2
doi: 10.1016/j.pscychresns.2024.111830
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111830

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declared no financial disclosures or conflict of interest.

Auteurs

Margaux Poireau (M)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France; FHU NOR-SUD (Network of Research in Substance Use Disorders), Paris, France. Electronic address: Margaux.poireau@aphp.fr.

Shailendra Segobin (S)

Normandie Univ, UNICAEN, PSL Université Paris, EPHE, INSERM, U1077, CHU de Caen, Cyceron, Neuropsychologie et Imagerie de la Mémoire Humaine (NIMH), 14000 Caen, France.

Angéline Maillard (A)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France.

Virgile Clergue-Duval (V)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France.

Romain Icick (R)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France.

Julien Azuar (J)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France.

Emmanuelle Volle (E)

FRONT-Lab, ICM, Institut du Cerveau, Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris, France.

Christine Delmaire (C)

INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France; Service de Neuroradiologie, Fondation Ophtalmologique Rothschild, 75019 Paris, France.

Vanessa Bloch (V)

INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France; FHU NOR-SUD (Network of Research in Substance Use Disorders), Paris, France; Service de Pharmacie à Usage Intérieur, Hôpital Fernand Widal, APHP.NORD, Paris, France.

Anne-Lise Pitel (AL)

Normandie Univ, UNICAEN, INSERM, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood and Brain @ Caen-Normandie, Cyceron, 14000 Caen, France; Institut Universitaire de France (IUF), France.

Florence Vorspan (F)

Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP.NORD, Paris, F-75010, France; INSERM UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, Université Paris Cité, Paris, F-75006, France; FHU NOR-SUD (Network of Research in Substance Use Disorders), Paris, France.

Classifications MeSH